• Jefferies Presentation

  • About Us

    Developing high-value products for patients in niche indications with significant unmet medical need

  • FDA extends PDUFA goal date for Nefecon NDA to December 15, 2021

Vision and Strategy

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Our Pipeline

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Share Price: Sweden

Share Price: US

Interim Report Q2 2021

On August 19, 2021, at 07:00 CEST, Calliditas Therapeutics published its interim report for the second quarter 2021.

Audio cast with teleconference, Q2 2021, August 19, 2021, 14:30 (Europe/Stockholm)